Silvia Careccia

Silvia Careccia

Auto-generated profile, based on publicly available information

Silvia Careccia

Institute of General Pathology, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Rome, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
IMIsabella Manni
Isabella Manni
SASimona Artuso
Simona Artuso
SCSilvia Careccia
Silvia Careccia
MRMaria Giulia Rizzo
Maria Giulia Rizzo
RBRenato Baserga
Renato Baserga
ASAda Sacchi
Ada Sacchi
MicroRNAs (miRs) are 21‐ to 23‐nucleo‐tide RNA molecules that regulate the stability or trans‐lational efficiency of target messenger RNAs of proteins involved in cell growth and apoptosis. miR‐92 is part of the mir‐17‐92 cluster, which comprises members with an effect on cell proliferation. However, the role of miR‐92 is unknown, and its targets have not been identified. Here, we describe a mechanism through which miR‐92 contributes to regulate cell proliferation. Using a miR‐92 synthetic double‐strand oligonucleotide, we demonstrate that miR‐92 increases 32D myeloid cell proliferation and 5‐bromo‐2‐deoxyuridine (BrdU) incorporation and inhibits cell death. The effect is miR‐92 specific since the miR‐92 antagomir inhibits cell proliferation. Moreover, we show that miR‐92 acts by modulating p63‐isoform abundance through down‐regulatation of endogenous ΔNp6β. Using luciferase reporters containing p63 3'UTR fragments with wild‐type or mutant miR‐92 complementary sites, we demonstrate that the wild‐type 3'UTR is a direct target of miR‐92. Finally, we observed that a miR‐92‐resistant ΔNp63β isoform (without 3'UTR) inhibits cell proliferation and parallels the effect of the antagomir. We conclude that one of the molecular mechanisms through which miR‐92 increases cell proliferation is by negative regulation of an isoform of the cell‐cycle regulator p63.—Manni, I., Artuso, S., Careccia, S., Rizzo, M. G., Baserga, R., Piaggio, G., Sacchi, A. The microRNA miR‐92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEBJ. 23, 3957‐3966 (2009). www.fasebj.org

8 January 2020 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FFFederica Francescangeli
Federica Francescangeli
PCPaola Contavalli
Paola Contavalli
MAMaria Laura De Angelis
Maria Laura De Angelis
SCSilvia Careccia
Silvia Careccia
MSMichele Signore
Michele Signore
AZAnn Zeuner
Ann Zeuner
Background: Quiescent/slow cycling cells have been identified in several tumors and correlated with therapy resistance. However, the features of chemoresistant populations and the molecular factors linking quiescence to chemoresistance are largely unknown. Methods: A population of chemoresistant quiescent/slow cycling cells was isolated through PKH26 staining (which allows to separate cells on the basis of their proliferation rate) from colorectal cancer (CRC) xenografts and subjected to global gene expression and pathway activation analyses. Factors expressed by the quiescent/slow cycling population were analyzed through lentiviral overexpression approaches for their ability to induce a dormant chemoresistant state both in vitro and in mouse xenografts. The correlation between quiescence-associated factors, CRC consensus molecular subtype and cancer prognosis was analyzed in large patient datasets. Results: Untreated colorectal tumors contain a population of quiescent/slow cycling cells with stem cell features (quiescent cancer stem cells, QCSCs) characterized by a predetermined mesenchymal-like chemoresistant phenotype. QCSCs expressed increased levels of ZEB2, a transcription factor involved in stem cell plasticity and epithelial-mesenchymal transition (EMT), and of antiapototic factors pCRAF and pASK1. ZEB2 overexpression upregulated pCRAF/pASK1 levels resulting in increased chemoresistance, enrichment of cells with stemness/EMT traits and proliferative slowdown of tumor xenografts. In parallel, chemotherapy treatment of tumor xenografts induced the prevalence of QCSCs with a stemness/EMT phenotype and activation of the ZEB2/pCRAF/pASK1 axis, resulting in a chemotherapy-unresponsive state. In CRC patients, increased ZEB2 levels correlated with worse relapse-free survival and were strongly associated to the consensus molecular subtype 4 (CMS4) characterized by dismal prognosis, decreased proliferative rates and upregulation of EMT genes. Conclusions: These results show that chemotherapy-naive tumors contain a cell population characterized by a coordinated program of chemoresistance, quiescence, stemness and EMT. Such population becomes prevalent upon drug treatment and is responsible for chemotherapy resistance, thus representing a key target for more effective therapeutic approaches.

14 September 2009 in Oncogene
Verified
Journal Article
Closed access
PDF file
SCS Careccia
S Careccia
SMS Mainardi
S Mainardi
APAndrea Pelosi
Andrea Pelosi
Aymone GurtnerAymone Gurtner
Aymone Gurtner
DDD Diverio
D Diverio
MRMaria Giulia Rizzo
Maria Giulia Rizzo

10 September 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
APAndrea Pelosi
Andrea Pelosi
SCS Careccia
S Careccia
VLValentina Lulli
Valentina Lulli
PRP Romania
P Romania
GMGiovanna Marziali
Giovanna Marziali
MRMaria Giulia Rizzo
Maria Giulia Rizzo
MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal proliferation and differentiation of leukemic cells. Recently, we reported that a small subset of miRNAs is differentially expressed in acute promyelocytic leukemia (APL) blasts and is modulated by treatment with all-trans-retinoic acid (ATRA). In particular, PML/RARα-positive blasts from APL patients display lower levels of miRNA let-7c, a member of the let-7 family, than normal promyelocytes and its expression increases after ATRA treatment. In this study, we investigated the effects of let-7c in acute myeloid leukemia (AML) cells. We found that ectopic expression of let-7c promotes granulocytic differentiation of AML cell lines and primary blasts. Moreover, we identified PBX2, a well-known homeodomain protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, as a novel let-7c target that may contribute to the AML phenotype. Together, these studies raise the possibility that perturbation of the let-7c-PBX2 pathway may have a therapeutic value in AML.

1 June 2014 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
APAndrea Pelosi
Andrea Pelosi
SCSilvia Careccia
Silvia Careccia
GSGiulia Sagrestani
Giulia Sagrestani
SNSimona Nanni
Simona Nanni
IMIsabella Manni
Isabella Manni
MRMaria Giulia Rizzo
Maria Giulia Rizzo
Let-7c, an intronic microRNA (miRNA) embedded in the long non-coding gene LINC00478, can act as a tumor suppressor by targeting oncogenes. Previous studies indicated that in acute promyelocytic leukemia (APL), a subtype of acute myelogenous leukemia (AML) bearing the leukemia promoting PML/RARα fusion protein, let-7c expression seems to be controlled by the host gene promoter, in which canonical Retinoic Acid Responsive Elements (RAREs) are bound by PML/RARα in an all transretinoic acid (ATRA)–sensitive manner. Here, let-7c transcriptional regulation was further investigated and a novel intronic promoter upstream of the pre-miRNA was identified. This new promoter has transcriptional activity strongly indicating that at least two promoters need to be considered for let-7c transcription: the distal host gene and the proximal intronic promoter. Therefore, epigenetic modifying enzymes and histone acetylation and methylation status were analyzed on both let-7c promoters. It was demonstrated that ATRA treatment leads to let-7c upregulation inducing a more open chromatin conformation of the host gene promoter, with an enrichment of epigenetic marks that correlate with a more active transcriptional state. Conversely, the epigenetic marks on the intronic promoter are not significantly affected by ATRA treatment. Interestingly, in solid tumors such as prostate and lung adenocarcinoma it was found that both host and intronic promoters are functional. These data suggest that while the host gene promoter may control let-7c expression in AML, in a nonleukemic tumor context instead the intronic promoter contributes or preferentially regulates let-7c transcription. Implications: Alternative promoter usage represents a regulatory mechanism of let-7c expression in different tissues. Mol Cancer Res; 12(6); 878–89. ©2014 AACR.

Verified
Journal Article
Open access
PDF file
LVLidia Villanova
Lidia Villanova
SCSilvia Careccia
Silvia Careccia
RMRuggero De Maria
Ruggero De Maria
MFMicol Eleonora Fiori
Micol Eleonora Fiori
In the last few years, non-coding RNAs (ncRNAs) have been a hot topic in cancer research. Many ncRNAs were found to regulate the apoptotic process and to play a role in tumor cell resistance to treatment. The apoptotic program is on the frontline as self-defense from cancer onset, and evasion of apoptosis has been classified as one of the hallmarks of cancer responsible for therapy failure. The B-cell lymphoma 2 (BCL-2) family members are key players in the regulation of apoptosis and mediate the activation of the mitochondrial death machinery in response to radiation, chemotherapeutic agents and many targeted therapeutics. The balance between the pro-survival and the pro-apoptotic BCL-2 proteins is strictly controlled by ncRNAs. Here, we highlight the most common mechanisms exerted by microRNAs, long non-coding RNAs and circular RNAs on the main mediators of the intrinsic apoptotic cascade with particular focus on their significance in cancer biology.